Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7488MR)

This product GTTS-WQ7488MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7488MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15920MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ1900MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ1235MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ1944MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ70MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ14647MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ13367MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ1655MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACT-017
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW